Historical Stock Chart
3 Months : From Oct 2019 to Jan 2020
By Michael Dabaie
Amgen Inc. (AMGN), Cytokinetics Inc. (CYTK) and Servier announced that new results from a Phase 2 trial showed omecamtiv mecarbil in patients with heart failure with reduced ejection fraction was associated with neutral or improved measures of diastolic function.
In addition to previously reported improvements in cardiac contractility measures, measures of diastolic function weren't different from placebo and, for some measures, trended towards improvement, the companies said.
In the COSMIC-HF trial, 448 patients were randomly assigned to omecamtiv mecarbil or placebo in a double-blind fashion for 20 weeks.
Write to Michael Dabaie at email@example.com
(END) Dow Jones Newswires
November 18, 2019 09:31 ET (14:31 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.